Latest news with #Lupins
The Herald Scotland
a day ago
- Lifestyle
- The Herald Scotland
Alan Titchmarsh's 5 showstopping plants every gardens need
The host of Love Your Weekend explains: 'So what makes a showstopper? Well, quite simply, it's a plant that can stop you in your tracks when you walk out into the garden.' How do I make my garden look pretty? Alan Titchmarsh's top 5 plants Lupins – Cashmere Cream Alan comments: 'This is a glorious border perennial, shortish seasonal flower. But these tall spires of bloom are shown off by the starry leaves, almost like a firework from that central stalk. 'Slightly smaller flowers will emerge from lower down the stem if you chop this off [the main Lupin stalk] once it's faded." The 76-year-old shares Lupins, which 'remind him of his childhood in Yorkshire' come in all sorts of colours, including blues, purples, reds, yellows and whites. He adds: 'Imagine walking into your garden and having some of these in your border because on a warm sunny day, you get a sweet fragrance from them as well. It's a pretty good all-rounder, the Lupin.' Ever thought about planting Lupins in your garden? (Image: Paul Maguire/Getty) Foxglove – Illumination Flame 'This one is rather unusual, it's called Illumination Flame, but if this ain't the showstopper, I don't know what is,' Alan says. The Gardening Club presenter continues: 'The lovely thing about Foxgloves is they will seed themselves around your garden. These amazing twin spires of beautiful flowers are rather different from normal Foxgloves, which are much more rounded at the edge of the petals.' Alan reveals a lot of them are biennials, which means you sow them one spring to flower the following year, and after that, 'they will die down and disappear, but they will still shed their seed'. He recommends Foxglove Illumination Flames as they are 'glorious' and grow in most soils and partial shade. Alan explains: 'For me, to bring some beauty with a kind of natural flavour and feel to the garden, the Foxglove is matchless and in this case a definite showstopper.' Poisonous Plants Found in the UK Penstemon – Laura The Penstemon Laura variety has 'deep dark plum flowers' known as 'Blackbird' or 'Sour Grapes' with purple and green flowers. Alan says: 'For the front or the middle of a border, they are smashing, they'll arrest your eye but they will carry on blooming right the way through the summer until the frost.' Dahlia – Muchacha Once planted in the spring, these 'superb' plants bloom from midsummer right until the frost of autumn, according to Alan. He shares they are 'full of flowers and great for cutting' and come in all sorts of sizes and colours, except 'true blue'. The 'gorgeous' flowers are quite 'juicy,' which means they like to live in moist soil (but not waterlogged). It's best to avoid planting them in 'dusty sand' otherwise they will make 'really poor plants'. Alan adds: 'In good, reasonably rich earth and full sun, they will flower their socks off. They are a true showstopper.' Delphinium - Highlander Bolero This bright, 'statuesque' plant can 'stop you in your tracks at the other end of the garden' and if grown well, can each up to seven or eight feet tall. To grow 'spectacular' Delphiniums, which are Alan's number one choice, he recommends using 'loads of muck, well-rotted garden compost, and to make the soil as rich as you possibly can.' But be warned, because this makes it attractive to slugs and snails. How to Get Rid of These Common Garden Pests So to manage this, Alan advises: 'When those shoots are emerging from the ground in March, April, control your slugs and snails then and you'll find these healthy shoots will shoot up and produce these glorious spires of flowers with smaller ones coming from the sides.' Recommended reading: He continues: 'When the central one fades, you can cut it off and get (albeit smaller ones), these side shoots coming up, with their own show of flowers.' Alan describes the Highlander Bolero flowers as 'almost like cake decorations' due to the double layers. His top tip is to cut them back once flowered and 'feed them well' in summer to 'boost them for next year'.
Business Standard
5 days ago
- Business
- Business Standard
Lupin joins hands with Sandoz to commercialize biosimilar Ranibizumab across multiple regions
Lupin has announced a strategic partnership with Switzerland-based Sandoz Group AG (Sandoz) to market and commercialize its biosimilar ranibizumab across multiple regions. Under the agreement, Sandoz will handle commercialization of the biosimilar across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and managing regulatory submissions. In most designated markets, Sandoz will have exclusive marketing rights, while in France, Australia, Vietnam, and Malaysia, the rights will be semi-exclusive. Additionally, through a separate agreement, Sandoz will acquire sole commercialization rights for Lupins biosimilar ranibizumab in Canada, with Lupin continuing to manage manufacturing and regulatory filings. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularization (CNV). Thierry Volle, President EMEA and Emerging Markets, Lupin, said, We are delighted to partner with Sandoz for the launch and commercialization of ranibizumab in multiple markets globally. This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupins consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25. The counter rose 0.45% to Rs 1,955 on the BSE.
Business Standard
06-08-2025
- Business
- Business Standard
Lupin Q1 PAT climbs 52% YoY to Rs 1,219 cr in FY26
Lupin's consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25. Profit before tax (PBT) rose 42.55% YoY to Rs 1415.54 crore in Q1 FY26. EBITDA stood at Rs 1,806.3 crore in Q1 FY26, registering the growth of 38% compared with Rs 1,308.8 crore in Q1 FY25. EBITDA margin improved 560 bps to 29.3% in Q1 June 2025 from 23.7% in Q1 June 2024. U.S. sales for Q1 FY2026 were Rs 2,404.1 crore up 24.3% compared to Rs 1,933.7 crore in Q1 FY2025. accounting for 39% of Lupins global sales. India sales for Q1 FY2026 were Rs 2,089.4 crore, up 7.8% compared to Rs 1,938.1 crore in Q1 FY2025; accounting for 34% of Lupins global sales. Revenue from other developed markets for Q1 FY2026 were Rs 774.8 crore, up 17.4% compared to Rs 660.0 crore in Q1 FY2025; accounting for 13% of Lupins global sales. Emerging markets sales rose 5.2% to Rs 652.4 crore in Q1 FY26 compared with Rs 620.3 crore in Q1 FY24. Global API sales for Q1 FY2026 were Rs 243.1 crore, down 32.9% compared to Rs 362.2 crore in Q1 FY2025; accounting for 4% of Lupins global sales. Investment in R&D was Rs 484.4 crore (7.9% of sales) for the quarter as compared to Rs 350.0 crore (6.3% of sales) for Q1 FY2025. The pharmaceutical company received approval for 2 ANDAs from the USFDA in the quarter. Cumulative ANDA filings with the USFDA stood at 442 as of June 30, 2025, with the company having received 342 approvals to date. Nilesh Gupta, managing director, Lupin, said We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Business Standard
24-04-2025
- Business
- Business Standard
Lupin rallies after receiving USFDA nod for Tolvaptan tablets
Lupin rose 1.09% to Rs 2,111.55 after the global pharmaceutical major received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tolvaptan Tablets. The drug is bioequivalent to Jynarque Tablets by Otsuka Pharmaceutical Company. Lupin is the exclusive first-to-file applicant for this product, making it eligible for 180 days of generic market exclusivity in the U.S. market. The product will be manufactured at Lupins Nagpur facility in India and is expected to launch soon. Tolvaptan is used to treat hyponatremia (low sodium levels in the blood) in patients with heart failure or syndrome of inappropriate antidiuretic hormone (SIADH). It is also approved to slow the progression of kidney function decline in adults at risk of rapidly advancing autosomal dominant polycystic kidney disease (ADPKD). The approved product has estimated annual sales of USD 1,467 million in the U.S. for the fiscal year ended 31 December 2024. Vinita Gupta, CEO of Lupin, said,We are very pleased to have obtained approval for generic Tolvaptan from the U.S. FDA. This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally. Mumbai-based Lupin is an innovation-led, transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Lupins consolidated net profit jumped 38.81% to Rs 858.86 crore on a 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 compared to Q3 FY24.
